X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs VENUS REMEDIES - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA VENUS REMEDIES TORRENT PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 36.9 -2.8 - View Chart
P/BV x 6.5 0.1 6,208.3% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
VENUS REMEDIES
Mar-18
TORRENT PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,550126 1,231.1%   
Low Rs1,14461 1,871.5%   
Sales per share (Unadj.) Rs354.7301.8 117.5%  
Earnings per share (Unadj.) Rs40.1-24.9 -161.1%  
Cash flow per share (Unadj.) Rs64.22.5 2,523.8%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.1293.3 93.1%  
Shares outstanding (eoy) m169.2212.34 1,371.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.80.3 1,225.6%   
Avg P/E ratio x33.6-3.8 -893.9%  
P/CF ratio (eoy) x21.036.7 57.1%  
Price / Book Value ratio x4.90.3 1,546.6%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,8971,154 19,752.0%   
No. of employees `00014.70.9 1,589.2%   
Total wages/salary Rs m11,353393 2,887.9%   
Avg. sales/employee Rs Th4,083.04,026.1 101.4%   
Avg. wages/employee Rs Th772.3425.0 181.7%   
Avg. net profit/employee Rs Th461.3-331.8 -139.0%   
INCOME DATA
Net Sales Rs m60,0213,724 1,611.7%  
Other income Rs m2,98823 13,281.8%   
Total revenues Rs m63,0093,747 1,681.8%   
Gross profit Rs m13,493395 3,417.6%  
Depreciation Rs m4,086338 1,207.8%   
Interest Rs m3,085354 870.7%   
Profit before tax Rs m9,310-275 -3,381.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,52932 8,002.2%   
Profit after tax Rs m6,781-307 -2,209.6%  
Gross profit margin %22.510.6 212.0%  
Effective tax rate %27.2-11.5 -236.6%   
Net profit margin %11.3-8.2 -137.1%  
BALANCE SHEET DATA
Current assets Rs m52,6232,638 1,995.1%   
Current liabilities Rs m52,0222,305 2,257.2%   
Net working cap to sales %1.08.9 11.2%  
Current ratio x1.01.1 88.4%  
Inventory Days Days120135 88.3%  
Debtors Days Days7646 164.5%  
Net fixed assets Rs m85,0164,871 1,745.4%   
Share capital Rs m846123 685.7%   
"Free" reserves Rs m45,3763,496 1,298.1%   
Net worth Rs m46,2223,619 1,277.2%   
Long term debt Rs m41,1151,374 2,991.5%   
Total assets Rs m142,4327,509 1,896.9%  
Interest coverage x4.00.2 1,802.0%   
Debt to equity ratio x0.90.4 234.2%  
Sales to assets ratio x0.40.5 85.0%   
Return on assets %6.90.6 1,097.3%  
Return on equity %14.7-8.5 -173.0%  
Return on capital %14.21.6 897.1%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m14,5800-   
Fx outflow Rs m3,600517 697.0%   
Net fx Rs m10,980-517 -2,125.9%   
CASH FLOW
From Operations Rs m8,942514 1,738.3%  
From Investments Rs m-47,070-123 38,236.8%  
From Financial Activity Rs m34,174-387 -8,828.2%  
Net Cashflow Rs m-3,6554 -87,023.8%  

Share Holding

Indian Promoters % 71.5 32.9 217.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.2 3,900.0%  
FIIs % 12.6 0.6 2,172.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 66.4 13.3%  
Shareholders   26,511 20,121 131.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  FDC LTD.  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Where Will the Two-Faced Market Go from Here?(Podcast)

The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

Feb 4, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)

Feb 5, 2019

A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Do You Have the Stomach to Survive a Small Cap Crash?(Profit Hunter)

Feb 5, 2019

While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 15, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS